Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Stopped early · Phase 3

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.

Key facts

Study ID
NCT03520686
Run by
ImmunityBio, Inc.
People needed
102
Starts
2018-05-18
Expected to finish
2025-10-13
Last updated by the study team
2026-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.